Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

NCT05660538 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.

Details

Lead sponsor	Vertex Pharmaceuticals Incorporated
Phase	PHASE2
Status	COMPLETED
Enrolment	194
Start date	Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetic Peripheral Neuropathy

Interventions

• Suzetrigine
• Pregabalin
• Placebo (matched to SUZ)
• Placebo (matched to pregabalin)

Countries

United States